Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide

A. Bennett, N J Shaw, J. Gregg, N. Subhedar

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Inhaled nitric oxide (iNO) is used to treat preterm infants with hypoxaemic respiratory failure. In this study we describe the long-term survival and neurodevelopmental status of high-risk preterm infants enrolled into a randomized controlled trial of iNO therapy. Information regarding long-term outcome was available for all 25 children enrolled in the original trial who survived until discharge from hospital. Formal, blinded, developmental assessment and neurological examinations were performed in 21 out of 22 children still alive at 30 mo of age, corrected for prematurity. No significant differences were found in long-term mortality (12/20 vs 8/22, RR 1.65, 95% CI 0.87-3.3), neurodevelopmental delay (4/7 vs 9/14, RR 0.89, 95% CI 0.37-1.75), severe neurodisability (0/7 vs 5/14, p = 0.12) or cerebral palsy (0/7 vs 2/14, p = 0.53) between iNO-treated and control infants. CONCLUSION: In this study there was no evidence of a significant effect on either survival or long-term neurodevelopmental status in infants treated with iNO.
Original languageEnglish
Pages (from-to)573-576
JournalActa Paediatrica Sinica
Volume90
Issue number5
Publication statusPublished - 2001

Fingerprint

Premature Infants
Nitric Oxide
Neurologic Examination
Cerebral Palsy
Respiratory Insufficiency
Randomized Controlled Trials
Mortality
Therapeutics

Cite this

Bennett, A., Shaw, N. J., Gregg, J., & Subhedar, N. (2001). Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide. Acta Paediatrica Sinica, 90(5), 573-576.
Bennett, A. ; Shaw, N J ; Gregg, J. ; Subhedar, N. / Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide. In: Acta Paediatrica Sinica. 2001 ; Vol. 90, No. 5. pp. 573-576.
@article{2dfda8e4332b422cb052ffa8f04bd3ab,
title = "Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide",
abstract = "Inhaled nitric oxide (iNO) is used to treat preterm infants with hypoxaemic respiratory failure. In this study we describe the long-term survival and neurodevelopmental status of high-risk preterm infants enrolled into a randomized controlled trial of iNO therapy. Information regarding long-term outcome was available for all 25 children enrolled in the original trial who survived until discharge from hospital. Formal, blinded, developmental assessment and neurological examinations were performed in 21 out of 22 children still alive at 30 mo of age, corrected for prematurity. No significant differences were found in long-term mortality (12/20 vs 8/22, RR 1.65, 95{\%} CI 0.87-3.3), neurodevelopmental delay (4/7 vs 9/14, RR 0.89, 95{\%} CI 0.37-1.75), severe neurodisability (0/7 vs 5/14, p = 0.12) or cerebral palsy (0/7 vs 2/14, p = 0.53) between iNO-treated and control infants. CONCLUSION: In this study there was no evidence of a significant effect on either survival or long-term neurodevelopmental status in infants treated with iNO.",
author = "A. Bennett and Shaw, {N J} and J. Gregg and N. Subhedar",
year = "2001",
language = "English",
volume = "90",
pages = "573--576",
journal = "Pediatrics and Neonatology",
issn = "1875-9572",
publisher = "Chinese Electronic Periodical Services",
number = "5",

}

Bennett, A, Shaw, NJ, Gregg, J & Subhedar, N 2001, 'Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide', Acta Paediatrica Sinica, vol. 90, no. 5, pp. 573-576.

Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide. / Bennett, A.; Shaw, N J; Gregg, J.; Subhedar, N.

In: Acta Paediatrica Sinica, Vol. 90, No. 5, 2001, p. 573-576.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide

AU - Bennett, A.

AU - Shaw, N J

AU - Gregg, J.

AU - Subhedar, N.

PY - 2001

Y1 - 2001

N2 - Inhaled nitric oxide (iNO) is used to treat preterm infants with hypoxaemic respiratory failure. In this study we describe the long-term survival and neurodevelopmental status of high-risk preterm infants enrolled into a randomized controlled trial of iNO therapy. Information regarding long-term outcome was available for all 25 children enrolled in the original trial who survived until discharge from hospital. Formal, blinded, developmental assessment and neurological examinations were performed in 21 out of 22 children still alive at 30 mo of age, corrected for prematurity. No significant differences were found in long-term mortality (12/20 vs 8/22, RR 1.65, 95% CI 0.87-3.3), neurodevelopmental delay (4/7 vs 9/14, RR 0.89, 95% CI 0.37-1.75), severe neurodisability (0/7 vs 5/14, p = 0.12) or cerebral palsy (0/7 vs 2/14, p = 0.53) between iNO-treated and control infants. CONCLUSION: In this study there was no evidence of a significant effect on either survival or long-term neurodevelopmental status in infants treated with iNO.

AB - Inhaled nitric oxide (iNO) is used to treat preterm infants with hypoxaemic respiratory failure. In this study we describe the long-term survival and neurodevelopmental status of high-risk preterm infants enrolled into a randomized controlled trial of iNO therapy. Information regarding long-term outcome was available for all 25 children enrolled in the original trial who survived until discharge from hospital. Formal, blinded, developmental assessment and neurological examinations were performed in 21 out of 22 children still alive at 30 mo of age, corrected for prematurity. No significant differences were found in long-term mortality (12/20 vs 8/22, RR 1.65, 95% CI 0.87-3.3), neurodevelopmental delay (4/7 vs 9/14, RR 0.89, 95% CI 0.37-1.75), severe neurodisability (0/7 vs 5/14, p = 0.12) or cerebral palsy (0/7 vs 2/14, p = 0.53) between iNO-treated and control infants. CONCLUSION: In this study there was no evidence of a significant effect on either survival or long-term neurodevelopmental status in infants treated with iNO.

M3 - Article

VL - 90

SP - 573

EP - 576

JO - Pediatrics and Neonatology

JF - Pediatrics and Neonatology

SN - 1875-9572

IS - 5

ER -